996 related articles for article (PubMed ID: 12869661)
1. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI
Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661
[TBL] [Abstract][Full Text] [Related]
2. Ecstasy: are animal data consistent between species and can they translate to humans?
Easton N; Marsden CA
J Psychopharmacol; 2006 Mar; 20(2):194-210. PubMed ID: 16510478
[TBL] [Abstract][Full Text] [Related]
3. Interactions between 3,4-methylenedioxymethamphetamine and ethanol in humans and rodents.
Mohamed WM; Hamida SB; de Vasconcelos AP; Cassel JC; Jones BC
Neuropsychobiology; 2009; 60(3-4):188-94. PubMed ID: 19893335
[TBL] [Abstract][Full Text] [Related]
4. A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy.
Colado MI; O'Shea E; Granados R; Misra A; Murray TK; Green AR
Br J Pharmacol; 1997 Jun; 121(4):827-33. PubMed ID: 9208155
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions.
Bankson MG; Cunningham KA
J Pharmacol Exp Ther; 2001 Jun; 297(3):846-52. PubMed ID: 11356903
[TBL] [Abstract][Full Text] [Related]
6. Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones.
Sanchez V; O'shea E; Saadat KS; Elliott JM; Colado MI; Green AR
J Psychopharmacol; 2004 Sep; 18(3):412-6. PubMed ID: 15358986
[TBL] [Abstract][Full Text] [Related]
7. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.
Colado MI; O'Shea E; Granados R; Esteban B; Martín AB; Green AR
Br J Pharmacol; 1999 Feb; 126(4):911-24. PubMed ID: 10193771
[TBL] [Abstract][Full Text] [Related]
8. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
9. Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.
Shioda K; Nisijima K; Yoshino T; Kuboshima K; Iwamura T; Yui K; Kato S
Neurotoxicology; 2008 Nov; 29(6):1030-6. PubMed ID: 18722468
[TBL] [Abstract][Full Text] [Related]
10. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response.
Green AR; O'shea E; Colado MI
Eur J Pharmacol; 2004 Oct; 500(1-3):3-13. PubMed ID: 15464016
[TBL] [Abstract][Full Text] [Related]
11. Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.
Colado MI; O'Shea E; Green AR
Psychopharmacology (Berl); 2004 May; 173(3-4):249-63. PubMed ID: 15083264
[TBL] [Abstract][Full Text] [Related]
12. Long-term neuronal damage and recovery after a single dose of MDMA: expression and distribution of serotonin transporter in the rat brain.
Kirilly E
Neuropsychopharmacol Hung; 2010 Sep; 12(3):413-23. PubMed ID: 20962361
[TBL] [Abstract][Full Text] [Related]
13. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT.
Shankaran M; Yamamoto BK; Gudelsky GA
Synapse; 2001 Apr; 40(1):55-64. PubMed ID: 11170222
[TBL] [Abstract][Full Text] [Related]
14. Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug.
Camarasa J; Pubill D; Escubedo E
Brain Res; 2006 Sep; 1111(1):72-82. PubMed ID: 16889759
[TBL] [Abstract][Full Text] [Related]
15. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research.
Clemens KJ; McGregor IS; Hunt GE; Cornish JL
Drug Alcohol Rev; 2007 Jan; 26(1):9-15. PubMed ID: 17364831
[TBL] [Abstract][Full Text] [Related]
16. MDMA-induced serotonergic neurotoxicity enhances aggressiveness in low- but not high-aggressive rats.
Wallinga AE; ten Voorde AM; de Boer SF; Koolhaas JM; Buwalda B
Eur J Pharmacol; 2009 Sep; 618(1-3):22-7. PubMed ID: 19616536
[TBL] [Abstract][Full Text] [Related]
17. Increased effects of 3,4-methylenedioxymethamphetamine (ecstasy) in a rat model of depression.
Jaehne EJ; Majumder I; Salem A; Irvine RJ
Addict Biol; 2011 Jan; 16(1):7-19. PubMed ID: 20192951
[TBL] [Abstract][Full Text] [Related]
18. MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats.
Clemens KJ; Cornish JL; Li KM; Hunt GE; McGregor IS
Neuropharmacology; 2005 Aug; 49(2):195-207. PubMed ID: 15993443
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxicity mechanisms of thioether ecstasy metabolites.
Capela JP; Macedo C; Branco PS; Ferreira LM; Lobo AM; Fernandes E; Remião F; Bastos ML; Dirnagl U; Meisel A; Carvalho F
Neuroscience; 2007 Jun; 146(4):1743-57. PubMed ID: 17467183
[TBL] [Abstract][Full Text] [Related]
20. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
